Search Results

Filter
  • 1-10 of  4,164 results for ""MAP Kinase Kinase 1""

Your Filters

Reset filters
Item request has been placed! ×
Item request cannot be made. ×
loading  Processing Request
Academic Journal

MAP kinase kinase 1 (MEK1) within extracellular vesicles inhibits tumour growth by promoting anti-tumour immunity.

  • Authors : Searles SC; Department of Pathology, University of California, San Diego, California, USA.; Chen WS

Subjects: Extracellular Vesicles*/Extracellular Vesicles*/Extracellular Vesicles*/metabolism ; Extracellular Vesicles*/Extracellular Vesicles*/Extracellular Vesicles*/immunology ; MAP Kinase Kinase 1*/MAP Kinase Kinase 1*/MAP Kinase Kinase 1*/metabolism

  • Source: Journal of extracellular vesicles [J Extracell Vesicles] 2024 Oct; Vol. 13 (10), pp. e12515.Publisher: Wiley Country of Publication: United States NLM ID: 101610479 Publication Model: Print Cited Medium: Internet ISSN: 2001-3078

Record details

×
Academic Journal

MEK1/2 promote ROS production and deubiquitinate NLRP3 independent of ERK1/2 during NLRP3 inflammasome activation.

  • Authors : Chen H; Department of Gastroenterology, The Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, 310009, PR China.; Xie S

Subjects: NLR Family, Pyrin Domain-Containing 3 Protein*/NLR Family, Pyrin Domain-Containing 3 Protein*/NLR Family, Pyrin Domain-Containing 3 Protein*/metabolism ; NLR Family, Pyrin Domain-Containing 3 Protein*/NLR Family, Pyrin Domain-Containing 3 Protein*/NLR Family, Pyrin Domain-Containing 3 Protein*/genetics ; Reactive Oxygen Species*/Reactive Oxygen Species*/Reactive Oxygen Species*/metabolism

  • Source: Biochemical pharmacology [Biochem Pharmacol] 2024 Dec; Vol. 230 (Pt 1), pp. 116572. Date of Electronic Publication: 2024 Oct 11.Publisher: Elsevier Science Country of Publication: England NLM ID: 0101032 Publication Model: Print-Electronic Cited Medium: Internet ISSN:

Record details

×
Academic Journal

Combined MEK1/2 and ATR inhibition promotes myeloma cell death through a STAT3-dependent mechanism in vitro and in vivo.

  • Authors : Li L; Division of Hematology/Oncology, Department of Internal Medicine, Virginia Commonwealth University, Richmond, Virginia, USA.; Hu X

Subjects: STAT3 Transcription Factor*/STAT3 Transcription Factor*/STAT3 Transcription Factor*/metabolism ; Ataxia Telangiectasia Mutated Proteins*/Ataxia Telangiectasia Mutated Proteins*/Ataxia Telangiectasia Mutated Proteins*/antagonists & inhibitors ; Ataxia Telangiectasia Mutated Proteins*/Ataxia Telangiectasia Mutated Proteins*/Ataxia Telangiectasia Mutated Proteins*/metabolism

  • Source: British journal of haematology [Br J Haematol] 2024 Dec; Vol. 205 (6), pp. 2338-2348. Date of Electronic Publication: 2024 Oct 08.Publisher: Wiley-Blackwell Country of Publication: England NLM ID: 0372544 Publication Model: Print-Electronic Cited Medium: Internet ISSN:

Record details

×
Academic Journal

Trametinib for a child with refractory Rosai-Dorfman-Destombes disease harboring a novel somatic mutation in MAP2K1.

  • Authors : Taneyama Y; Department of Hematology/Oncology, Chiba Children's Hospital, Chiba, Japan.; Morimoto A

Subjects: Pyrimidinones*/Pyrimidinones*/Pyrimidinones*/therapeutic use ; Histiocytosis, Sinus*/Histiocytosis, Sinus*/Histiocytosis, Sinus*/drug therapy ; Histiocytosis, Sinus*/Histiocytosis, Sinus*/Histiocytosis, Sinus*/genetics

  • Source: International journal of hematology [Int J Hematol] 2024 Oct; Vol. 120 (4), pp. 520-524. Date of Electronic Publication: 2024 Jul 14.Publisher: Springer Japan Country of Publication: Japan NLM ID: 9111627 Publication Model: Print-Electronic Cited Medium: Internet ISSN:

Record details

×
Academic Journal

MEK Inhibition in the Treatment of Congenital Langerhans Cell Histiocytosis: A Case Report and Review of the Literature.

Subjects: Histiocytosis, Langerhans-Cell*/Histiocytosis, Langerhans-Cell*/Histiocytosis, Langerhans-Cell*/drug therapy ; Histiocytosis, Langerhans-Cell*/Histiocytosis, Langerhans-Cell*/Histiocytosis, Langerhans-Cell*/congenital ; Histiocytosis, Langerhans-Cell*/Histiocytosis, Langerhans-Cell*/Histiocytosis, Langerhans-Cell*/genetics

  • Source: Journal of pediatric hematology/oncology [J Pediatr Hematol Oncol] 2024 Oct 01; Vol. 46 (7), pp. 383-387. Date of Electronic Publication: 2024 Aug 05.Publisher: Lippincott Williams & Wilkins Country of Publication: United States NLM ID: 9505928 Publication Model: Print-Electronic Cited Medium:

Record details

×
Report

Experience with trametinib in a pediatric patient with MAP2K1-related cervicofacial arteriovenous malformation.

  • Authors : Swaminathan N; Department of Pediatrics, Pediatric Hematology Oncology, University of Michigan, Ann Arbor, Michigan, USA.; Smith JD

Subjects: Pyrimidinones*/Pyrimidinones*/Pyrimidinones*/therapeutic use ; Pyridones*/Pyridones*/Pyridones*/therapeutic use ; MAP Kinase Kinase 1*/MAP Kinase Kinase 1*/MAP Kinase Kinase 1*/antagonists & inhibitors

  • Source: Pediatric blood & cancer [Pediatr Blood Cancer] 2024 Nov; Vol. 71 (11), pp. e31298. Date of Electronic Publication: 2024 Aug 27.Publisher: John Wiley Country of Publication: United States NLM ID: 101186624 Publication Model: Print-Electronic Cited Medium: Internet ISSN:

Record details

×
Academic Journal

Ganglioglioma with MAP2K1 Mutation and CDKN2A/B Homozygous Deletion: A Case Report.

  • Authors : Zhao C; Department of Neuro-Oncology, Sanbo Brain Hospital, Capital Medical University, Beijing, China.; Li C

Subjects: Ganglioglioma*/Ganglioglioma*/Ganglioglioma*/genetics ; Ganglioglioma*/Ganglioglioma*/Ganglioglioma*/pathology ; Brain Neoplasms*/Brain Neoplasms*/Brain Neoplasms*/genetics

  • Source: British journal of hospital medicine (London, England : 2005) [Br J Hosp Med (Lond)] 2024 Oct 30; Vol. 85 (10), pp. 1-10. Date of Electronic Publication:Publisher: MA Healthcare Country of Publication: England NLM ID: 101257109 Publication Model: Print-Electronic Cited Medium: Internet ISSN:

Record details

×
Academic Journal

Integrin α1 upregulation by TF:FVIIa complex promotes cervical cancer migration through PAR2-dependent MEK1/2 activation.

Subjects: Receptor, PAR-2*/Receptor, PAR-2*/Receptor, PAR-2*/metabolism ; Receptor, PAR-2*/Receptor, PAR-2*/Receptor, PAR-2*/genetics ; Cell Movement*

  • Source: Biochemical and biophysical research communications [Biochem Biophys Res Commun] 2025 Jan; Vol. 742, pp. 151151. Date of Electronic Publication: 2024 Dec 05.Publisher: Elsevier Country of Publication: United States NLM ID: 0372516 Publication Model: Print-Electronic Cited Medium: Internet ISSN:

Record details

×
Academic Journal

An Unexpected Finding of a PTPN11 Germline Mutation in a Patient With a Melanocytic Lesion With a Somatic MAP2K1 Mutation. Coincidence or Not?

Subjects: Germ-Line Mutation* ; Protein Tyrosine Phosphatase, Non-Receptor Type 11*/Protein Tyrosine Phosphatase, Non-Receptor Type 11*/Protein Tyrosine Phosphatase, Non-Receptor Type 11*/genetics ; Melanoma*/Melanoma*/Melanoma*/genetics

  • Source: Journal of cutaneous pathology [J Cutan Pathol] 2025 Jan; Vol. 52 (1), pp. 20-23. Date of Electronic Publication: 2024 Oct 11.Publisher: Wiley Country of Publication: United States NLM ID: 0425124 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1600-0560

Record details

×
Academic Journal

Recurrent p.H119Y variant in MAP2K1 expands the phenotypic spectrum of MAP2K1 -related RASopathy.

Subjects: MAP Kinase Kinase 1*/MAP Kinase Kinase 1*/MAP Kinase Kinase 1*/genetics ; Heart Defects, Congenital*/Heart Defects, Congenital*/Heart Defects, Congenital*/genetics ; Heart Defects, Congenital*/Heart Defects, Congenital*/Heart Defects, Congenital*/pathology Cardiofaciocutaneous syndrome

  • Source: American journal of medical genetics. Part A [Am J Med Genet A] 2025 Jan; Vol. 197 (1), pp. e63854. Date of Electronic Publication: 2024 Aug 21.Publisher: Wiley-Blackwell Country of Publication: United States NLM ID: 101235741 Publication Model: Print-Electronic Cited Medium: Internet ISSN:

Record details

×
  • 1-10 of  4,164 results for ""MAP Kinase Kinase 1""